RAPIDO |
cT4, or EMVI+, CN2, MRF+, or LPLN+ |
450 |
Standard: 5FU-CRT→Surgery→ ±FOLFOX(12)/CAPOX(8) |
14.3 |
*DRTF: 30 |
89 |
462 |
Consolidation: SCRT→FOLFOX(9)/CAPOX(6)→Surgery |
28.42 |
*DRTF: 24*DRTF: |
89 |
PRODIGE-23 |
cT3 or cT4 |
230 |
Standard: 5FU-CRT→Surgery→mFOLFOX/capecitabine(3) |
12.1 |
62.5 |
76.1 |
231 |
Induction: FOLFIRINOX(6)→ 5FU-CRT→Surgery→mFOLFOX/capecitabine(6) |
27.8 |
67.6 |
81.9 |
POLISH II |
Primary or locally recurrent cT4, or a palpable fixed cT3 |
254 |
Standard: 5FU/OX-CRT→Surgery→± ChT |
12 |
43 |
49 |
261 |
Consolidation: SCRT→FOLFOX(3)→Surgery→± ChT |
16 |
41 |
49 |
STELLAR |
Primary cT3–4 or N+ in mid to distal rectum |
293 |
Standard: CAPE-CRT→Surgery→CAPOX(6) |
12.3 |
62 |
75 |
298 |
Consolidation: SCRT→CAPOX(4)→Surgery→CAPOX(2) |
21.8 |
65 |
87 |
CAO/ARO/AIO-12 |
cT3 if < 6 cm from AV; > cT3b if 6–12 cm from AV; cT4, or LPLN+ |
156 |
Consolidation: 5FU/OX-RT→FOLFOX(3)→Surgery |
25 |
73 |
92 |
150 |
Induction: FOLFOX(3)→ 5FU/OX-CRT→Surgery |
17 |
73 |
92 |
OPRA |
AJCC stage III–IV |
155 |
Consolidation: 5FU-CRT→ FOLFOX/CAPOX(4 mo)→Surgery |
NR |
76 |
NR |
152 |
Induction: FOLFOX/CAPOX(4 mo)→5FU-CRT→Surgery |
NR |
76 |
NR |